Also, selective estrogen receptor modulators used in combination with anti-HER2 treatment in patients with HER2+ and ER+ BC, such as tamoxifen and raloxifene, can change the composition of the gut microbiome (85–89). Here, ERBB2 is linked to breast cancer.